Employees: 5,546
Size Jeena Sikho Lifecare (JSLL.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $394M, the 956th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹296.35 on 18 Nov 2026.
Performance Over six months the shares fell 54.7%, against -3.5% for the median peer and +3.8% for the India market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 135.3% over the last twelve months (peer median +5.1%); the operating margin is 31.6% (peer median 8.0%).
Valuation It trades at 17.4× forward earnings against a peer median of 17.1× (7th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +43%, so the hurdle is -35 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 39.4 points above its cost of capital (12.6% WACC).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹8.97B | ₹8.01B | ₹4.69B | ₹3.24B | ₹2.04B |
| Revenue growth | — | +71% | +45% | +59% | — |
| Gross profit | ₹5.57B | ₹5.10B | ₹2.81B | ₹2.17B | ₹1.35B |
| EBITDA | ₹3.43B | ₹3.52B | ₹1.42B | ₹936M | ₹464M |
| Net income | ₹2.14B | ₹2.22B | ₹799M | ₹692M | ₹337M |
| Free cash flow | n/a | ₹2.21B | ₹452M | ₹238M | -₹219M |
| Capital expenditure | n/a | ₹341M | ₹423M | ₹155M | ₹392M |
| Total debt | ₹1.68B | ₹1.27B | ₹1.17B | ₹5.39M | ₹8.08M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | JSLL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.9% | -6.8% | 5th lowest of 21 |
| 6-month return | -54.7% | -3.5% | 2nd lowest of 20 |
| Distance from 52-week high | -63.4% | -26.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | +135.3% | +5.1% | highest of 21 |
| Operating margin | 31.6% | 8.0% | highest of 21 |
| Forward P/E | 17.4× | 17.1× | 7th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 7.3% | 5.6% | 8th most demanding of 17 |
| Growth delivered (Del g) | +42.6% | +15.4% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | -35.3 pp | -10.9 pp | 2nd least demanding of 17 |
| ROIC minus cost of capital | +39.4 pp | -2.5 pp | highest of 20 |
| EV / EBITDA | 10.4× | 8.8× | 6th most expensive of 13 |
| Net debt / EBITDA | -0.3× | 1.6× | 5th least indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 24.6× | 12.3% | -1.5% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 16.4× | -5.3% | +17.9% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | n/a | -14.9% | +9.6% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | n/a | 18.8% | -5.8% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | n/a | 5.4% | +21.8% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 19.8× | 3.4% | +15.3% |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 4.1× | -10.7% | +24.4% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 9.2× | -13.8% | +15.4% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | n/a | 19.6% | +27.5% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |